Alterations in the serotonin system in schizophrenia: A systematic review and meta-analysis of postmortem and molecular imaging studies

Neuroscience and Biobehavioral Reviews

Volumn 45, Issue , 2014, Pages 233-245

  Selvaraj, Sudhakar ^a,b   Arnone, Danilo ^c   Cappai, Alessandra ^a,d   Howes, Oliver ^a,c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF TEXAS   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d SPRINGFIELD HOSPITAL   (United Kingdom)

Author keywords

5 HT1A receptor; 5 HT2A receptor; Neuroimaging; Positron emission tomography (PET); Postmortem; Prefrontal cortex; Psychosis; Schizophrenia; Serotonin or 5 HT

Indexed keywords

SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN 4 RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; TRACER;

AUTOPSY; EFFECT SIZE; HUMAN; IN VIVO STUDY; META ANALYSIS (TOPIC); MOLECULAR IMAGING; NEUROIMAGING; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOSIS; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SYSTEMATIC REVIEW; BRAIN; META ANALYSIS; METABOLISM;

BRAIN; HUMANS; MOLECULAR IMAGING; RECEPTORS, SEROTONIN; SCHIZOPHRENIA;

EID: 84904059514     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2014.06.005     Document Type: Review

References (136)

1. Abbas A.I., Hedlund P.B., Huang X.P., Tran T.B., Meltzer H.Y., Roth B.L. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl.) 2009, 205(1):119-128.
2. Abel K.M., O'Keane V., Murray R.M., Cleare A.J. Serotonergic function and negative and depressive symptomatology in schizophrenia and major depression. Psychoneuroendocrinology 1997, 22(7):539-548.
3. Abi-Dargham A. Alterations of serotonin transmission in schizophrenia. Int. Rev. Neurobiol. 2007, 78:133-164.
4. Abi-Dargham A., Laruelle M., Lipska B., Jaskiw G.E., Wong D.T., Robertson D.W., et al. Serotonin 5-HT3 receptors in schizophrenia: a postmortem study of the amygdala. Brain Res. 1993, 616(1-2):53-57.
5. Abi-Saab W., Seibyl J.P., D'Souza D.C., Karper L.P., Gueorgueva R., Abi-Dargham A., et al. Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms. Psychopharmacology (Berl.) 2002, 162(1):55-62.
6. Aghajanian G.K., Marek G.J. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res. Brain Res. Rev. 2000, 31(2-3):302-312.
7. Ago Y., Koyama Y., Baba A., Matsuda T. Regulation by 5-HT1A receptors of the in vivo release of 5-HT and DA in mouse frontal cortex. Neuropharmacology 2003, 45(8):1050-1056.
8. Arango B. Neuroanatomy of Serotonergic Abnormalities in Suicide 2012, CRC Press, Boca Raton, FL.
9. Arango V., Underwood M.D., Gubbi A.V., Mann J.J. Localized alterations in pre- and postsynaptic serotonin binding sites in the ventrolateral prefrontal cortex of suicide victims. Brain Res. 1995, 688(1-2):121-133.
10. Arborelius L., Chergui K., Murase S., Nomikos G.G., Höök B.B., Chouvet G., et al. The 5-HT1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons. Naunyn Schmiedebergs Arch. Pharmacol. 1993, 347(4):353-362.
11. Arnone D., Cavanagh J., Gerber D., Lawrie S.M., Ebmeier K.P., McIntosh A.M. Magnetic resonance imaging studies in bipolar disorder and schizophrenia: meta-analysis. Br. J. Psychiatry 2009, 195(3):194-201.
12. Arnone D., McIntosh A.M., Ebmeier K.P., Munafò M.R., Anderson I.M. Magnetic resonance imaging studies in unipolar depression: systematic review and meta-regression analyses. Eur. Neuropsychopharmacol. 2012, 22(1):1-16.
13. Arora R.C., Meltzer H.Y. Serotonin2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients. J. Neural Transm. Gen. Sect. 1991, 85(1):19-29.
14. Bantick R.A., Montgomery A.J., Bench C.J., Choudhry T., Malek N., McKenna P.J., et al. A positron emission tomography study of the 5-HT1A receptor in schizophrenia and during clozapine treatment. J. Psychopharmacol. 2004, 18(3):346-354.
15. Barnes N.M., Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999, 38(8):1083-1152.
16. Bennett J.P., Enna S.J., Bylund D.B., Gillin J.C., Wyatt R.J., Snyder S.H. Neurotransmitter receptors in frontal cortex of schizophrenics. Arch. Gen. Psychiatry 1979, 36(9):927-934.
17. Berton O., McClung C.A., Dileone R.J., Krishnan V., Renthal W., Russo S.J., et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 2006, 311(5762):864-868.
18. Buckley P.F., Miller B.J., Lehrer D.S., Castle D.J. Psychiatric comorbidities and schizophrenia. Schizophr. Bull. 2009, 35(2):383-402.
19. Burnet P.W., Eastwood S.L., Harrison P.J. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 1996, 15(5):442-455.
20. 3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem. Int. 1997, 30(6):565-574.
21. Carpenter L.L., Anderson G.M., Pelton G.H., Gudin J.A., Kirwin P.D., Price L.H., et al. Tryptophan depletion during continuous CSF sampling in healthy human subjects. Neuropsychopharmacology 1998, 19(1):26-35.
22. Celada P., Bortolozzi A., Artigas F. Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS Drugs 2013, 27(9):703-716.
23. Coyle J.T. The GABA-glutamate connection in schizophrenia: which is the proximate cause?. Biochem. Pharmacol. 2004, 68(8):1507-1514.
24. Coyle J.T. NMDA receptor and schizophrenia: a brief history. Schizophr. Bull. 2012, 38(5):920-926.
25. Cruz D.A., Eggan S.M., Azmitia E.C., Lewis D.A. Serotonin1A receptors at the axon initial segment of prefrontal pyramidal neurons in schizophrenia. Am. J. Psychiatry 2004, 161(4):739-742.
26. Dayan P., Huys Q.J. Serotonin, inhibition, and negative mood. PLoS Comput. Biol. 2008, 4(2):e4.
27. Dean B. The cortical serotonin2A receptor and the pathology of schizophrenia: a likely accomplice. J. Neurochem. 2003, 85(1):1-13.
28. Dean B., Crossland N., Boer S., Scarr E. Evidence for altered post-receptor modulation of the serotonin 2a receptor in schizophrenia. Schizophr. Res. 2008, 104(1-3):185-197.
29. Dean B., Hayes W. Decreased frontal cortical serotonin2A receptors in schizophrenia. Schizophr. Res. 1996, 21(3):133-139.
30. Dean B., Hayes W., Opeskin K., Naylor L., Pavey G., Hill C., et al. Serotonin2 receptors and the serotonin transporter in the schizophrenic brain. Behav. Brain Res. 1996, 73(1-2):169-175.
31. 3H]paroxetine binding is altered in the hippocampus but not the frontal cortex or caudate nucleus from subjects with schizophrenia. J. Neurochem. 1995, 64(3):1197-1202.
32. Dean B., Pavey G., Thomas D., Scarr E. Cortical serotonin7, 1D and 1F receptors: effects of schizophrenia, suicide and antipsychotic drug treatment. Schizophr. Res. 2006, 88(1-3):265-274.
33. Dean B., Tomaskovic-Crook E., Opeskin K., Keks N., Copolov D. No change in the density of the serotonin1A receptor, the serotonin4 receptor or the serotonin transporter in the dorsolateral prefrontal cortex from subjects with schizophrenia. Neurochem. Int. 1999, 34(2):109-115.
34. Demeter E., Tekes K., Majorossy K., Palkovits M., Soós M., Magyar K., et al. The asymmetry of 3H-imipramine binding may predict psychiatric illness. Life Sci. 1989, 44(19):1403-1410.
35. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 1986, 7(3):177-188.
36. Drevets W.C., Frank E., Price J.C., Kupfer D.J., Holt D., Greer P.J., et al. PET imaging of serotonin 1A receptor binding in depression. Biol. Psychiatry 1999, 46(10):1375-1387.
37. Eastwood S.L., Burnet P.W., Gittins R., Baker K., Harrison P.J. Expression of serotonin 5-HT(2A) receptors in the human cerebellum and alterations in schizophrenia. Synapse 2001, 42(2):104-114.
38. Egerton A., Chaddock C.A., Winton-Brown T.T., Bloomfield M.A., Bhattacharyya S., Allen P., et al. Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort. Biol. Psychiatry 2013, 74(2):106-112.
39. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315(7109):629-634.
40. Fakra E., Hyde L.W., Gorka A., Fisher P.M., Munoz K.E., Kimak M., et al. Effects of HTR1A C(-1019)G on amygdala reactivity and trait anxiety. Arch. Gen. Psychiatry 2009, 66(1):33-40.
41. Finnema S.J., Stepanov V., Ettrup A., Nakao R., Amini N., Svedberg M., et al. Characterization of [(11)C]Cimbi-36 as an agonist PET radioligand for the 5-HT2A and 5-HT2C receptors in the nonhuman primate brain. Neuroimage 2013, 84C:342-353.
42. 11C]WAY 100635. Psychopharmacology (Berl.) 2006, 189(2):155-164.
43. 11C]DASB. Biol. Psychiatry 2005, 57(12):1510-1516.
44. Fu R., Gartlehner G., Grant M., Shamliyan T., Sedrakyan A., Wilt T.J., et al. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program. J. Clin. Epidemiol. 2011, 64(11):1187-1197.
45. Fuller R.W., Snoddy H.D., Robertson D.W. Mechanisms of effects of d-fenfluramine on brain serotonin metabolism in rats: uptake inhibition versus release. Pharmacol. Biochem. Behav. 1988, 30(3):715-721.
46. Fusar-Poli P., Valmaggia L., McGuire P. Can antidepressants prevent psychosis?. Lancet 2007, 370(9601):1746-1748.
47. Gaddum J.H., Hameed K.A. Drugs which antagonize 5-hydroxytryptamine. Br. J. Pharmacol. Chemother. 1954, 9(2):240-248.
48. Geyer M.A., Vollenweider F.X. Serotonin research: contributions to understanding psychoses. Trends Pharmacol. Sci. 2008, 29(9):445-453.
49. González-Maeso J., Ang R.L., Yuen T., Chan P., Weisstaub N.V., López-Giménez J.F., et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 2008, 452(7183):93-97.
50. Gray L., Scarr E., Dean B. Serotonin 1a receptor and associated G-protein activation in schizophrenia and bipolar disorder. Psychiatry Res. 2006, 143(2-3):111-120.
51. Green A.R. Neuropharmacology of 5-hydroxytryptamine. Br. J. Pharmacol. 2006, 147(Suppl. 1):S145-S152.
52. Gross C., Zhuang X., Stark K., Ramboz S., Oosting R., Kirby L., et al. Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature 2002, 416(6879):396-400.
53. Gurevich E.V., Joyce J.N. Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol. Psychiatry 1997, 42(7):529-545.
54. Hariri A.R., Mattay V.S., Tessitore A., Kolachana B., Fera F., Goldman D., et al. Serotonin transporter genetic variation and the response of the human amygdala. Science 2002, 297(5580):400-403.
55. Hashimoto T., Nishino N., Nakai H., Tanaka C. Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci. 1991, 48(4):355-363.
56. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327(7414):557-560.
57. Holmes A., Murphy D.L., Crawley J.N. Abnormal behavioral phenotypes of serotonin transporter knockout mice: parallels with human anxiety and depression. Biol. Psychiatry 2003, 54(10):953-959.
58. Howes O., Bose S., Turkheimer F., Valli I., Egerton A., Stahl D., et al. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Mol. Psychiatry 2011.
59. Howes O.D., Egerton A., Allan V., McGuire P., Stokes P., Kapur S. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr. Pharm. Des. 2009, 15(22):2550-2559.
60. Howes O.D., Kambeitz J., Kim E., Stahl D., Slifstein M., Abi-Dargham A., et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch. Gen. Psychiatry 2012, 69(8):776-786.
61. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III - the final common pathway. Schizophr. Bull. 2009, 35(3):549-562.
62. Howes O.D., Montgomery A.J., Asselin M.C., Murray R.M., Valli I., Tabraham P., et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch. Gen. Psychiatry 2009, 66(1):13-20.
63. 11C]AFM. J. Cereb. Blood Flow Metab. 2002, 22(11):1377-1398.
64. Hurlemann R., Matusch A., Kuhn K.U., Berning J., Elmenhorst D., Winz O., et al. 5-HT2A receptor density is decreased in the at-risk mental state. Psychopharmacology (Berl.) 2008, 195(4):579-590.
65. Ichikawa J., Ishii H., Bonaccorso S., Fowler W.L., O'Laughlin I.A., Meltzer H.Y. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 2001, 76(5):1521-1531.
66. Javitt D.C. Twenty-five years of glutamate in schizophrenia: are we there yet?. Schizophr. Bull. 2012, 38(5):911-913.
67. Johnson D.A. Depressions in schizophrenia: some observations on prevalence, etiology, and treatment. Acta Psychiatr. Scand. Suppl. 1981, 291:137-144.
68. Joyce J.N., Shane A., Lexow N., Winokur A., Casanova M.F., Kleinman J.E. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 1993, 8(4):315-336.
69. Kang K., Huang X.F., Wang Q., Deng C. Decreased density of serotonin 2A receptors in the superior temporal gyrus in schizophrenia - a postmortem study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33(5):867-871.
70. Kim E., Howes O.D., Turkheimer F.E., Kim B.H., Jeong J.M., Kim J.W., et al. The relationship between antipsychotic D2 occupancy and change in frontal metabolism and working memory: a dual [(11)C]raclopride and [(18)F]FDG imaging study with aripiprazole. Psychopharmacology (Berl.) 2013, 227(2):221-229.
71. Koreen A.R., Siris S.G., Chakos M., Alvir J., Mayerhoff D., Lieberman J. Depression in first-episode schizophrenia. Am. J. Psychiatry 1993, 150(11):1643-1648.
72. Kosmidis M.H., Bozikas V.P., Giannakou M., Anezoulaki D., Fantie B.D., Karavatos A. Impaired emotion perception in schizophrenia: a differential deficit. Psychiatry Res. 2007, 149(1-3):279-284.
73. Kouzmenko A.P., Scaffidi A., Pereira A.M., Hayes W.L., Copolov D.L., Dean B. No correlation between A(-1438)G polymorphism in 5-HT2A receptor gene promoter and the density of frontal cortical 5-HT2A receptors in schizophrenia. Hum. Hered. 1999, 49(2):103-105.
74. Kristiansen H., Elfving B., Plenge P., Pinborg L.H., Gillings N., Knudsen G.M. Binding characteristics of the 5-HT2A receptor antagonists altanserin and MDL 100907. Synapse 2005, 58(4):249-257.
75. Laruelle M., Abi-Dargham A., Casanova M.F., Toti R., Weinberger D.R., Kleinman J.E. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. Arch. Gen. Psychiatry 1993, 50(10):810-818.
76. Laruelle M., Abi-Dargham A., van Dyck C., Gil R., D'Souza D.C., Krystal J., et al. Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT. Biol. Psychiatry 2000, 47(5):371-379.
77. 123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993, 13(4):295-309.
78. 18F]setoperone in neuroleptic-naive patients and normal subjects. Am. J. Psychiatry 1999, 156(1):72-78.
79. Lodge D.J., Grace A.A. Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia. Trends Pharmacol. Sci. 2011, 32(9):507-513.
80. Lovenberg T.W., Baron B.M., de Lecea L., Miller J.D., Prosser R.A., Rea M.A., et al. A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms. Neuron 1993, 11(3):449-458.
81. Lowther S., De Paermentier F., Cheetham S.C., Crompton M.R., Katona C.L., Horton R.W. 5-HT1A receptor binding sites in post-mortem brain samples from depressed suicides and controls. J. Affect. Disord. 1997, 42(2-3):199-207.
82. Lucki I. The spectrum of behaviors influenced by serotonin. Biol. Psychiatry 1998, 44(3):151-162.
83. Lundberg J., Odano I., Olsson H., Halldin C., Farde L. Quantification of 11C-MADAM binding to the serotonin transporter in the human brain. J. Nucl. Med. 2005, 46(9):1505-1515.
84. 11C]MDL 100907, a radioligland for selective imaging of 5-HT(2A) receptors with positron emission tomography. Life Sci. 1996, 58(10):187-192.
85. Lyon R.A., Titeler M., Frost J.J., Whitehouse P.J., Wong D.F., Wagner H.N., et al. 3H-3-N-methylspiperone labels D2 dopamine receptors in basal ganglia and S2 serotonin receptors in cerebral cortex. J. Neurosci. 1986, 6(10):2941-2949.
86. Mackay A.V., Doble A., Bird E.D., Spokes E.G., Quik M., Iversen L.L. 3H-spiperone binding in normal and schizophrenic post-mortem human brain. Life Sci. 1978, 23(5):527-532.
87. Matsumoto I., Inoue Y., Iwazaki T., Pavey G., Dean B. 5-HT2A and muscarinic receptors in schizophrenia: a postmortem study. Neurosci. Lett. 2005, 379(3):164-168.
88. Maziere B., Crouzel C., Venet M., Stulzaft O., Sanz G., Ottaviani M., et al. Synthesis, affinity and specificity of 18F-setoperone, a potential ligand for in-vivo imaging of cortical serotonin receptors. Int. J. Radiat. Appl. Instrum. B 1988, 15(4):463-468.
89. Meltzer H.Y. Serotonergic mechanisms as targets for existing and novel antipsychotics. Handb. Exp. Pharmacol. 2012, (212):87-124.
90. Mita T., Hanada S., Nishino N., Kuno T., Nakai H., Yamadori T., et al. Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol. Psychiatry 1986, 21(14):1407-1414.
91. Mohr P., Horácek J., Motlová L., Libiger J., Czobor P. Prolactin response to d-fenfluramine challenge test as a predictor of treatment response to haloperidol in acute schizophrenia. Schizophr. Res. 1998, 30(1):91-99.
92. Monteleone P., Tortorella A., Borriello R., Cassandro P., Maj M. Prolactin hyperresponsiveness to d-fenfluramine in drug-free schizophrenic patients: a placebo-controlled study. Biol. Psychiatry 1999, 45(12):1606-1611.
93. Muguruza C., Moreno J.L., Umali A., Callado L.F., Meana J.J., González-Maeso J. Dysregulated 5-HT(2A) receptor binding in postmortem frontal cortex of schizophrenic subjects. Eur. Neuropsychopharmacol. 2012.
94. Nash J.R., Sargent P.A., Rabiner E.A., Hood S.D., Argyropoulos S.V., Potokar J.P., et al. Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study. Br. J. Psychiatry 2008, 193(3):229-234.
95. 3H]paroxetine. J. Neural Transm. 1996, 103(6):749-757.
96. Ngan E.T., Yatham L.N., Ruth T.J., Liddle P.F. Decreased serotonin 2A receptor densities in neuroleptic-naive patients with schizophrenia: a PET study using [(18)F]setoperone. Am. J. Psychiatry 2000, 157(6):1016-1018.
97. Nord M., Finnema S.J., Halldin C., Farde L. Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain. Int. J. Neuropsychopharmacol. 2013, 1-10.
98. Okubo Y., Suhara T., Suzuki K., Kobayashi K., Inoue O., Terasaki O., et al. Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomography. Life Sci. 2000, 66(25):2455-2464.
99. Owen F., Cross A.J., Crow T.J., Lofthouse R., Poulter M. Neurotransmitter receptors in brain in schizophrenia. Acta Psychiatr. Scand. Suppl. 1981, 291:20-28.
100. Parks C.L., Robinson P.S., Sibille E., Shenk T., Toth M. Increased anxiety of mice lacking the serotonin1A receptor. Proc. Natl. Acad. Sci. U.S.A. 1998, 95(18):10734-10739.
101. Parsey R.V., Oquendo M.A., Ogden R.T., Olvet D.M., Simpson N., Huang Y.Y., et al. Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol. Psychiatry 2006, 59(2):106-113.
102. 3H]spiroperidol. Mol. Pharmacol. 1979, 16(3):687-699.
103. Pralong D., Tomaskovic-Crook E., Opeskin K., Copolov D., Dean B. Serotonin(2A) receptors are reduced in the planum temporale from subjects with schizophrenia. Schizophr. Res. 2000, 44(1):35-45.
104. Ramboz S., Oosting R., Amara D.A., Kung H.F., Blier P., Mendelsohn M., et al. Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. Proc. Natl. Acad. Sci. U.S.A. 1998, 95(24):14476-14481.
105. Rao J.S., Kellom M., Reese E.A., Rapoport S.I., Kim H.W. Dysregulated glutamate and dopamine transporters in postmortem frontal cortex from bipolar and schizophrenic patients. J. Affect. Disord. 2012, 136(1-2):63-71.
106. Rasmussen H., Erritzoe D., Andersen R., Ebdrup B.H., Aggernaes B., Oranje B., et al. Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients with first-episode schizophrenia. Arch. Gen. Psychiatry 2010, 67(1):9-16.
107. Reynolds G.P., Rossor M.N., Iversen L.L. Preliminary studies of human cortical 5-HT2 receptors and their involvement in schizophrenia and neuroleptic drug action. J. Neural Transm. Suppl. 1983, 18:273-277.
108. Richardson-Jones J.W., Craige C.P., Nguyen T.H., Kung H.F., Gardier A.M., Dranovsky A., et al. Serotonin-1A autoreceptors are necessary and sufficient for the normal formation of circuits underlying innate anxiety. J. Neurosci. 2011, 31(16):6008-6018.
109. Santana N., Bortolozzi A., Serrats J., Mengod G., Artigas F. Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb. Cortex 2004, 14(10):1100-1109.
110. 11C]WAY-100635: effects of depression and antidepressant treatment. Arch. Gen. Psychiatry 2000, 57(2):174-180.
111. Scarr E., Pavey G., Copolov D., Dean B. Hippocampal 5-hydroxytryptamine receptors: abnormalities in postmortem brain from schizophrenic subjects. Schizophr. Res. 2004, 71(2-3):383-392.
112. Schneider F., Gur R.C., Koch K., Backes V., Amunts K., Shah N.J., et al. Impairment in the specificity of emotion processing in schizophrenia. Am. J. Psychiatry 2006, 163(3):442-447.
113. Selvaraj S., Turkheimer F., Rosso L., Faulkner P., Mouchlianitis E., Roiser J.P., et al. Measuring endogenous changes in serotonergic neurotransmission in humans: a [(11)C]CUMI-101 PET challenge study. Mol. Psychiatry 2012.
114. Sharma R.P., Shapiro L.E., Kamath S.K., Soll E.A., Watanabe M.D., Davis J.M. Acute dietary tryptophan depletion: effects on schizophrenic positive and negative symptoms. Neuropsychobiology 1997, 35(1):5-10.
115. Shaw E., Woolley D.W. Some serotoninlike activities of lysergic acid diethylamide. Science 1956, 124(3212):121-122.
116. 3H]8-OH-DPAT reveals increases in 5-HT(1A) receptors in ventral prefrontal cortex in schizophrenia. Biol. Psychiatry 1996, 39(11):919-928.
117. Singh S.P., Singh V., Kar N., Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br. J. Psychiatry 2010, 197(3):174-179.
118. Slater P., Doyle C.A., Deakin J.F. Abnormal persistence of cerebellar serotonin-1A receptors in schizophrenia suggests failure to regress in neonates. J. Neural Transm. 1998, 105(2-3):305-315.
119. Stockmeier C.A. Involvement of serotonin in depression: evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter. J. Psychiatr. Res. 2003, 37(5):357-373.
120. Stockmeier C.A., Dilley G.E., Shapiro L.A., Overholser J.C., Thompson P.A., Meltzer H.Y. Serotonin receptors in suicide victims with major depression. Neuropsychopharmacology 1997, 16(2):162-173.
121. Stone J.M., Howes O.D., Egerton A., Kambeitz J., Allen P., Lythgoe D.J., et al. Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. Biol. Psychiatry 2010, 68(7):599-602.
122. Strauss G.P., Kappenman E.S., Culbreth A.J., Catalano L.T., Lee B.G., Gold J.M. Emotion regulation abnormalities in schizophrenia: cognitive change strategies fail to decrease the neural response to unpleasant stimuli. Schizophr. Bull. 2013, 39(4):872-883.
123. Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283(15):2008-2012.
124. Sumiyoshi T., Stockmeier C.A., Overholser J.C., Dilley G.E., Meltzer H.Y. Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res. 1996, 708(1-2):209-214.
125. Tarazi F.I., Zhang K., Baldessarini R.J. Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology (Berl.) 2002, 161(3):263-270.
126. 11C]WAY-100635. Arch. Gen. Psychiatry 2002, 59(6):514-520.
127. 3H]-SB-269970 radiolabels 5-HT7 receptors in rodent, pig and primate brain tissues. Neuropharmacology 2002, 42(1):74-81.
128. Thompson S.G., Sharp S.J. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat. Med. 1999, 18(20):2693-2708.
129. Trichard C., Paillere-Martinot M.L., Attar-Levy D., Blin J., Feline A., Martinot J.L. No serotonin 5-HT2A receptor density abnormality in the cortex of schizophrenic patients studied with PET. Schizophr. Res. 1998, 31(1):13-17.
130. Tseng H.H., Chen S.H., Liu C.M., Howes O., Huang Y.L., Hsieh M.H., et al. Facial and prosodic emotion recognition deficits associate with specific clusters of psychotic symptoms in schizophrenia. PLoS ONE 2013, 8(6):e66571.
131. Tsoi D.T., Lee K.H., Khokhar W.A., Mir N.U., Swalli J.S., Gee K.A., et al. Is facial emotion recognition impairment in schizophrenia identical for different emotions? A signal detection analysis. Schizophr. Res. 2008, 99(1-3):263-269.
132. 18F]setoperone PET data shows no substantial serotonin 5-HT(2A) receptor changes in schizophrenia. Psychiatry Res. 2000, 99(3):123-135.
133. Weisstaub N.V., Zhou M., Lira A., Lambe E., González-Maeso J., Hornung J.P., et al. Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. Science 2006, 313(5786):536-540.
134. Whitaker P.M., Crow T.J., Ferrier I.N. Tritiated LSD binding in frontal cortex in schizophrenia. Arch. Gen. Psychiatry 1981, 38(3):278-280.
135. Yasuno F., Suhara T., Ichimiya T., Takano A., Ando T., Okubo Y. Decreased 5-HT1A receptor binding in amygdala of schizophrenia. Biol. Psychiatry 2004, 55(5):439-444.
136. Yung A.R., Yuen H.P., McGorry P.D., Phillips L.J., Kelly D., Dell'Olio M., et al. Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust. N. Z. J. Psychiatry 2005, 39(11-12):964-971.